Vulval Biopsy in India and UAE | Complete Patient Guide

• Women presenting with chronic or refractory vulvar pruritus, burning, pain, or dyspareunia unresponsive to 8–12 weeks of empirical treatment

• Any visible vulvar lesion: white (leukoplakia), red (erythroplakia), pigmented, ulcerated, warty, nodular, or indurated area that has not resolved spontaneously

• Suspected or confirmed VIN (high-grade squamous intraepithelial lesion / dVIN) identified on prior colposcopy or cytology

• Clinical suspicion of vulvar carcinoma (squamous cell, basal cell, melanoma, adenocarcinoma, or Paget's disease)

• Histological surveillance in patients with known lichen sclerosus or lichen planus with evolving clinical features

• Evaluation of chronic granulomatous lesions (e.g., Crohn's disease involving the vulva, hidradenitis suppurativa with ulceration)

• Bartholin gland cyst or abscess with atypical features in women over 40 years of age (to exclude adenocarcinoma)

• Required pre-procedural diagnostics and workup: Complete blood count (CBC), coagulation profile (PT/INR/APTT) to assess bleeding risk; Cervical smear / HPV genotyping (to assess concurrent lower genital tract involvement); Colposcopy with photodocumentation and lesion mapping; Dermatoscopy for pigmented lesions; HIV and immunosuppression status assessment; Pelvic ultrasound or MRI pelvis if a deep or invasive lesion is suspected clinically; Pregnancy test (urine or serum beta-hCG) if indicated

• Contraindications and special considerations: Active untreated coagulopathy or anticoagulation therapy (warfarin, DOACs) not bridged or paused per haematology guidance; Known allergy to local anaesthetic agents (alternative agents or general anaesthesia should be planned); Active vulvar infection (e.g., herpetic ulceration, bacterial cellulitis) — biopsy should be deferred until infection is treated to reduce false-negative histology and wound complications; Pregnancy is a relative contraindication; biopsy may proceed in the second trimester if malignancy is strongly suspected, after multidisciplinary team (MDT) review; Patients on immunosuppressive therapy require antibiotic prophylaxis consideration per institutional protocol

Vulval biopsy is not a single technique but a family of procedures selected based on lesion morphology, size, depth, number of lesion sites, and the degree of diagnostic certainty required. The following techniques are performed at GAF Healthcare's partner hospitals:

1. PUNCH BIOPSY (Most Common — Office/Outpatient Procedure): A Keyes punch biopsy instrument (2 mm, 3 mm, 4 mm, or 6 mm diameter) is used under local anaesthesia (1–2% lidocaine with or without adrenaline 1:100,000 for haemostasis). The punch is rotated with downward pressure to excise a cylindrical core of skin and subcutaneous tissue. This technique is ideal for flat, plaque-like, or papular lesions; it allows sampling of multiple sites in multifocal disease during a single sitting. Haemostasis is achieved with silver nitrate, Monsel's solution (ferric subsulfate), or a single absorbable suture (Vicryl 3-0 or 4-0). Colposcopy-guided punch biopsy — performed with real-time magnification and vascular pattern assessment — is the subspecialty gold standard, as it ensures the highest-grade or most vascularly abnormal area is sampled, maximising diagnostic yield.

2. SHAVE BIOPSY: Used for raised, exophytic, or pedunculated lesions (e.g., condylomata, fibromas, papillomas). A scalpel or razor blade removes a thin horizontal slice. This technique is fast and produces minimal scarring but provides limited depth assessment, making it unsuitable when stromal invasion needs to be excluded.

3. EXCISIONAL BIOPSY (Wide Local Excision): The gold standard when the entire lesion must be removed for complete histopathological assessment (e.g., pigmented lesions suspicious for melanoma, lesions where total excision is both diagnostic and therapeutic, or when punch biopsy is non-representative). Performed under local or general anaesthesia, the lesion is excised with a 5–10 mm margin. Primary closure is performed with interrupted or subcuticular absorbable sutures. In the setting of suspected melanoma, initial excisional biopsy with 1–2 mm margins (not wide margins) is recommended to preserve accurate sentinel lymph node mapping; wider re-excision follows after histological staging.

4. LOOP ELECTROSURGICAL EXCISION PROCEDURE (LLETZ/LEEP) ADAPTED FOR VULVA: For well-defined, accessible VIN lesions on keratinised skin, a fine-wire loop electrode under local anaesthesia provides simultaneous excision and haemostasis. Thermal artifact at specimen margins is a known limitation; specimen orientation and submission in formalin with ink-marking of margins is mandatory.

5. INCISIONAL BIOPSY: For large lesions where complete excision is not feasible or appropriate at the initial visit, an incisional biopsy — removing a representative wedge — is performed. This is particularly relevant in advanced or ulcerated lesions where primary surgery will await oncology MDT decision.

6. SENTINEL LYMPH NODE BIOPSY (SLNB) — Advanced Oncological Extension: In cases where vulval biopsy confirms early-stage (FIGO Stage IB–II) squamous cell carcinoma ≤4 cm without clinically suspicious nodes, SLNB using technetium-99m radiolabelled nanocolloid ± indocyanine green (ICG) near-infrared fluorescence mapping is performed at GAF Healthcare's partner tertiary oncology centres. This minimally invasive approach, validated by the GROINSS-V trial, replaces routine inguinofemoral lymphadenectomy in eligible patients, dramatically reducing the risk of lymphoedema (from ~30% to <5%).

7. ANAESTHESIA OPTIONS: The majority of vulval biopsies are performed under local anaesthesia (lidocaine 1–2% ± adrenaline) as outpatient procedures. EMLA cream (lidocaine/prilocaine) applied 45–60 minutes prior reduces injection discomfort. General or spinal anaesthesia is reserved for extensive mapping biopsies, excisional biopsies of deeply infiltrative lesions, paediatric patients, or patients with significant needle phobia or inability to cooperate.

8. DIGITAL PATHOLOGY & RAPID TURNAROUND: GAF Healthcare's partner hospitals utilise digital whole-slide imaging (WSI) platforms and subspecialty gynaecological pathology review, with standard histology results available within 48–72 hours and urgent intraoperative frozen-section analysis available where clinically indicated.

PRE-PROCEDURE (Days 1–3 before biopsy):

• Day 1: Telemedicine consultation with GAF Healthcare's partner gynaecologist or gynaecological oncologist. Review of previous biopsy reports, colposcopy images, imaging (MRI/ultrasound), and clinical photographs submitted digitally.

• Day 2: Arrival at destination (India or UAE). Airport-to-hospital/hotel transfer arranged by GAF Healthcare coordinator.

• Day 3: In-person clinical assessment. Colposcopy with lesion mapping and photodocumentation. Baseline blood tests (CBC, coagulation profile, blood group, beta-hCG if indicated). Anaesthesia pre-assessment if general anaesthesia is planned. Informed consent obtained with detailed discussion of biopsy technique, potential findings, and subsequent management pathways. Anticoagulant medications (aspirin, clopidogrel, warfarin, DOACs) paused as per haematology/physician guidance (typically 3–7 days prior for most agents).

PROCEDURE DAY:

• Outpatient or day-surgery unit admission. Duration: 15–45 minutes for punch or shave biopsy under local anaesthesia; 45–90 minutes for excisional biopsy under general or regional anaesthesia.

• Local anaesthetic injection (or EMLA pre-treatment). Colposcopy-guided site selection. Biopsy performed using selected technique (punch, shave, excisional, or LLETZ). Haemostasis secured. Specimen labelled, oriented with ink, and submitted in formalin for formal histopathology ± immunohistochemistry (p16, Ki-67, p53 staining for VIN grading and dVIN identification).

• Post-procedure observation: 1–2 hours for local anaesthesia cases; 4–6 hours for general anaesthesia cases.

• Discharge with written wound care instructions, topical antiseptic (e.g., povidone-iodine or chlorhexidine wash), non-adherent wound dressing guidance, and oral analgesia prescription (paracetamol ± ibuprofen; opioids rarely required).

POST-PROCEDURE RECOVERY — MILESTONES:

• Days 1–3: Mild localised discomfort, minor spotting or serosanguinous discharge expected. Sitz baths with warm water 2–3 times daily for hygiene and comfort. Avoid tight clothing, synthetic underwear, and prolonged sitting on hard surfaces. Sexual intercourse, swimming, and tampon use strictly avoided.

• Day 3–5: Sutures (if placed) are typically absorbable and do not require removal. Wound check by nurse or remote wound photograph review via GAF Healthcare's teleconsultation platform.

• Day 5–7: Histopathology results received. GAF Healthcare coordinator facilitates a teleconsult with the treating gynaecologist for result disclosure and next-step counselling. If benign — reassurance and topical therapy plan issued. If VIN or malignancy confirmed — MDT meeting convened; treatment plan communicated to patient and home-country oncologist.

• Fit-to-Fly Assessment: Patients undergoing local-anaesthesia punch biopsy are typically cleared for international travel at Day 3–5, provided the wound is dry, there is no infection, and the patient is comfortable seated for the flight duration. Patients who received general anaesthesia must wait a minimum of 7–10 days post-procedure and receive explicit written fit-to-fly clearance from the anaesthetist. All patients receive a comprehensive medical summary, operative report, histopathology report, and GP/oncologist referral letter in English for continuity of care at home.

• Week 2–4: Full wound healing. Resumption of normal physical activity including exercise. Follow-up plan (colposcopy surveillance, topical treatment commencement, or definitive surgery scheduling) communicated to home-country physician.